Articles

1561-1580 of 2004 < first | | | last >
  • IFPAC 2006 Under the Microscope

    "NIR person" and physical chemist Emil Ciurczak provides a thorough analysis of this year's IFPAC conference, held Feb. 21-23 in Arlington, Va.

    Emil W. Ciurczak, Chief Technical Officer, Cadrai Group
    03/03/2006
  • Ciurczak Analyzes IFPAC '06

    NIR expert and Pharmaceutical Manufacturing columnist Emil Ciurczak discusses this year's conference in this downloadable audio file. For his article discussing highlights and key developments, see "IFPAC 2006 Under the Microscope."

    Emil W. Ciurczak, Chief Technical Officer, Cadrai Group
    03/03/2006
  • Urban Legends and Misconceptions

    A successful industry means job security for both FDA and instrument vendors. They are on your side; talk with them. Don’t rely on “word of mouth” to make decisions about PAT.

    Emil W. Ciurczak, Chief Technical Officer, Cadrai Group
    03/01/2006
  • S-Factors: a Tactical PAT Kit

    When is an aspirin tablet like a yacht? According to Jack Carroll, this riddle's answer lies in five S-factors: Staff, Select, Strategize, Spend and finally, Supplant a GMP-tested product line with its PAT counterpart.

    John E. "Jack" Carroll, C.Ph.C., Managing Partner, Cadrai Technology Group
    03/01/2006
  • Applying PAT to Vaccine Manufacturing

    In this audio interview at IFPAC, Mathieu Streefland of the Netherlands Vaccine Institute discusses the progress his group is making toward applying PAT to the unwieldy world of vaccine manufacturing.

    Paul Thomas, Managing Editor
    02/28/2006
  • Indian Biotech: Rapidly Evolving, Industry Led

    Nandini Kumar of India's Council of Medical Research and his colleagues in India and Canada discuss developments in Indian biotech and issues shaping its future.

    Nandini Kumar et al.
    02/27/2006
  • Transgenics to Be a $12 Billion Market by 2012

    Kalorama analysts expect transgenics to become a $12 billion market by 2012. The first drug approvals using transgenics are expected this year, resulting in a $225 million market. Read about this new report.

    02/27/2006
  • Mining the Hidden Factory

    Overall equipment effectiveness (OEE) can be useful in developing a pharmaceutical manufacturing excellence program, and provide a welcome bottom-line boost.

    Robert C. Hansen, P.E.
    02/16/2006
  • A New Vaccine Supply Strategy

    Not one solution, but a combination of new technologies and simple approaches will be needed to prepare for the onslaught of flu and other diseases.

    Angelo De Palma, Ph.D., Contributing Editor
    02/16/2006
1561-1580 of 2004 < first | | | last >